Copyright
©The Author(s) 2015.
World J Med Genet. Feb 27, 2015; 5(1): 1-13
Published online Feb 27, 2015. doi: 10.5496/wjmg.v5.i1.1
Published online Feb 27, 2015. doi: 10.5496/wjmg.v5.i1.1
Table 1 Current cell mediated gene therapy protocols in clinical and R and D stages
Target disease | Stage | Gene modification | Target cell | Ref. |
Hemophilia A | Preclinical | Oct4, Sox2, Klf4 | Fibroblast | Xu et al[40] |
ALS | Preclinical | Oct4, Sox2, Klf4, c-Myc | Fibroblast | Dimos et al[55] |
Alzheimer | Preclinical | Oct4, Sox2, Klf4, c-Myc | Fibroblast | Israel et al[46] |
ALS | Preclinical | Oct4, Sox2, Klf4 | Fibroblast | Chen et al[54] |
Cardiac failure | Preclinical | Gata4, Mef2c, Tbx4 | Fibroblast | Ieda et al[22] |
Diabetes | Preclinical | Oct4, Sox2, Klf4 | Fibroblast | Zhang et al[24] |
Schizophrenia | Preclinical | Oct4, Sox2, Klf4, c-Myc | Fibroblast with 15q11.2 del | Yoon et al[12] |
Barth syndrome | Preclinical | Oct4, Sox2, Klf4, c-Myc | Fibroblast | Wang et al[52] |
Parkinson’s disease | Preclinical | Oct4, Sox2, Klf4, c-Myc | Fibroblast | Chung et al[50] |
Macular degeneration | PhaseI | Oct4, Sox2, Klf4, c-Myc | Fibroblast | Kamao et al[14] |
Degenerative arthritis | Phase II/III | TGF-β1 | Chondrocyte | Ha et al[15] |
X-linked adrenoleukodystrophy | In the clinic | ABCD1 | CD34+ Bone marrow cell | Cartier et al[36] |
Wiskott-aldrich syndrome | In the clinic | WASP | CD34+ Bone marrow cell | Aiuti et al[35] |
Metachromatic leukodystrophy | In the clinic | ARSA | CD34+ Bone marrow cell | Biffi et al[37] |
Table 2 Different types of production methods based on cells needed per batch
Cells/lot (billions) | Cell culture | Harvest | Filling | Freezing |
1 | T175 flask or hyperflask, 10 layer cell factory | Bucket centrifugation | Hand/manual fill | Bench top control rate freezer |
10 | 10 layer cell factory, hyperstack-12, Xpansion systems | Bucket centrifugation | Semi automated fill machine or hand/manual fill | Bench top control rate freezer |
50 | Hyperstack or Xpansion, cell cube | Tangential flow filtration, continuous centrifugation | Automated fill machine | Large scale control rate freezer |
100 | Factory automation of Xpansion or Hyperstack technologies | Tangential flow filtration of continuous centrifugation | Automated fill machine | Large scale control rate freezer |
500 | Bioreactors using microcarriers | Continuous centrifugation | Automated fill machine | Scale out large scale control rate freezer |
Table 3 Suggested release tests advised by Food and Drug Administration for cell product
Category | Test | Key measurement |
Sterility | Sterility | Microbiological testing |
Mycoplasma | After pooling of cultures but before washing | |
Identity | Identity | Cell identity and assess heterogeneity |
Purity | Impurity | Residuals contaminants |
Endotoxin | Contaminants during the process | |
Potency | Specific to product | Relevant function of the cells |
Other testing | General safety | Cellular therapy products are exempt |
Viability | Generally > 70% | |
Cell number | Minimum and maximum cell number | |
Title 21 of the code of federal regulations applied to cell therapy products | ||
The tissue rules: Part 1271 | ||
The biologics requirements: Part 600 and 610 | ||
The investigational new drug requirements: Part 312 | ||
The drug manufacturing requirements: Parts 211 and 212 |
Table 4 TG-C release test
Test | Method | Specification |
Release tests and specifications for hChonJ cell | ||
Identification | ||
Cell growth and morphology | Visual (test code 30117) | Fibroblast-like: spindle shaped/bipolar or multipolar cells |
Viability | Trypan blue dye exclusion | > 70% |
(test code 30458) | ||
Mycoplasma | 1993 Points to consider (test code 30055) | Negative |
RAP test | In vivo and ELISA (test code 30163) | Negative |
Sterility (direct inoculation method) | 21 CFR 610.12 (test code 30744) | Negative |
Endotoxin | LAL (test code 37653) | < 5 EU/mL |
Release tests and specifications for hChonJb#7 Cell | ||
Identity | Epithelial-like: fried egg or polygonal-shaped appearance | |
Cell growth and morphology | Visual (test code 30117) | |
Type II collagen assay | RT-PCR (test code 30412) | Type II collagen present |
TGF-β1 presence | PCR (test code 30959) | TGF-β1 present |
Potency (TGF-β1 assay) | ELISA (test code 30444) | 1-50 ng/105 cells/24 h |
Viability | Trypan blue dye exclusion (test code 30458) | > 70% |
RCR | Co-culture of end of production cells (test codes 30628) | Negative |
Supernatant amplification (test code 30633) | Negative | |
Mycoplasma | 1993 points to consider (test code 30055) | Negative |
Rat antibody production | In vivo and ELISA (test code 30163) | Negative |
Endotoxin | LAL (test code 37653) | < 5 EU/mL |
Sterility | 21 CFR 610.12 (test code 30744) | Negative |
- Citation: Noh MJ, Copeland O, O’Mara M, Lee KH. Cell mediated gene therapy: A guide for doctors in the clinic. World J Med Genet 2015; 5(1): 1-13
- URL: https://www.wjgnet.com/2220-3184/full/v5/i1/1.htm
- DOI: https://dx.doi.org/10.5496/wjmg.v5.i1.1